SalmaKahtanJabbourMD

Radiation Oncology • New Brunswick, NJ

Assistant Professor, Radiation Oncology, UMDNJ-Robert Wood Johnson Medical School

Join to view full profile

Dr. Jabbour is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jabbour's full profile

Already have an account?

Office
195 Little Albany St
Radiation Oncology
New Brunswick, NJ 08901
Phone+1 732-235-3939

Fax+1 732-235-7493

Education & Training

University of Maryland School of MedicineClass of 2001

Certifications & Licensure

NJ State Medical License 2006 - 2025
PA State Medical License 2004 - 2014
American Board of Radiology Radiation Oncology

Clinical Trials

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas Start of enrollment: 2023 Mar 16
Recruiting
Phase 2
Roles: Contact
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer Start of enrollment: 2021 Feb 11
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma Start of enrollment: 2022 Jul 25
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants Start of enrollment: 2024 Jan 30
Not yet recruiting
Phase 1
Roles: Principal Investigator, Contact
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer Start of enrollment: 2022 May 13
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Start of enrollment: 2017 Sep 29
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2018 Sep 06
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Recapping Radiation Related Abstracts at ASCO 2024: A Commentary about the Fundamental Role of Radiation Therapy in Esophageal and Lung Cancers.
Salma K Jabbour, Kristin A Higgins, Sue S Yom, Karyn A Goodman
International Journal of Radiation Oncology, Biology, Physics. 2024-10-01
Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radia...
Zachary S Zumsteg, Siddharth Sheth, Salma K Jabbour, Krishnan R Patel, Randall J Kimple
The Lancet. Oncology. 2024-10-01
Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortiu...
Jyoti Malhotra, Alberto Chiappori, Naomi Fujioka, Nasser H Hanna, Lawrence E Feldman
Lung Cancer. 2024-09-01

Authored Content

Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non–Small Cell Lung Cancer Are Associated with Decreases in Overall SurvivalMay 2018